|Bid||231.20 x 0|
|Ask||231.30 x 0|
|Day's Range||229.10 - 232.70|
|52 Week Range||177.45 - 245.50|
|Beta (5Y Monthly)||0.37|
|PE Ratio (TTM)||22.55|
|Earnings Date||Feb 08, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||255.44|
Subscribe to Yahoo Finance Plus to view Fair Value for SOBI.ST
Sobi plans to publish its report for the fourth quarter and full year of 2022 on 8 February 2023 at 08:00 CET.
Pivotal study data published in The New England Journal of Medicine (NEJM) continues to highlight the efficacy, safety, and pharmacokinetic profile of efanesoctocog alfa (formerly BIVV001), a potential new medicine for haemophilia A. These data demonstrate the clinical benefits of normal to near-normal factor activity levels (>40%) for the majority of the week achieved by once weekly efanesoctocog alfa dosing. Efanesoctocog alfa is currently under priority regulatory review in the US with a targ
Sobi® and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of Zynlonta® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval follows a positive opinion issued in September by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA).